Menu

Everest Re Group, Ltd. (EG)

$327.57
+0.41 (0.13%)
Get curated updates for this stock by email. We filter for the most important fundamentals-focused developments and send only the key news to your inbox.

Data provided by IEX. Delayed 15 minutes.

Market Cap

$13.7B

Enterprise Value

$11.9B

P/E Ratio

25.1

Div Yield

2.45%

Rev Growth YoY

+18.1%

Rev 3Y CAGR

+14.7%

Earnings YoY

-45.5%

Earnings 3Y CAGR

-0.1%

Company Profile

At a glance

Balance Sheet Surgery in Progress: Everest is aggressively excising its U.S. casualty cancer through $2.2 billion in reserve additions, a $1.2 billion adverse development cover, and exiting $2 billion in global retail insurance—actions that will either cure the patient or reveal deeper malignancy by 2026.

Reinsurance: The Hidden Gem: The Reinsurance segment delivered an 87% combined ratio in Q3 2025 while competitors struggle with cat volatility, generating over $100 million in underwriting income from Global Specialties alone—a business that should command a premium valuation but remains obscured by insurance segment losses.

Capital Inflection Point: The AIG (AIG) renewal rights sale and ADC transaction will release "meaningful total value" and "significant capital" according to management, funding a buyback program that has already repurchased $400 million year-to-date at prices below current book value—a clear signal of value recognition.

Price Chart

Loading chart...